Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: BLCO )

17.94 -0.47 (-2.55%)
Official Closing Price Updated: 7:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 282,760
Open 18.38
Bid (Size) 16.63 (1)
Ask (Size) 18.69 (1)
Prev. Close 18.41
Today's Range 17.83 - 18.50
52wk Range 12.20 - 19.96
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
9 Analysts Have This to Say About Bausch & Lomb
 
Via Benzinga
Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease
From Bausch + Lomb Corporation
Via Business Wire

Performance

YTD
+14.12%
+14.12%
1 Month
+5.41%
+5.41%
3 Month
+0.56%
+0.56%
6 Month
+22.37%
+22.37%
1 Year
+1.41%
+1.41%

More News

Read More
Looking Into Bausch & Lomb's Return On Capital Employed
Via Benzinga
Bausch & Lomb's Return On Capital Employed Insights
Via Benzinga
Inflationary Factors And Slow Product Uptake Could Be Headwinds For Bausch + Lomb, Analyst Says
Via Benzinga
Recap: Bausch & Lomb Q1 Earnings
Via Benzinga
Analyst Expectations for Bausch & Lomb's Future
Via Benzinga
The Latest Analyst Ratings for Bausch & Lomb
Via Benzinga
Bausch + Lomb Announces First-Quarter 2023 Results and Provides 2023 Guidance
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Releases Annual Environmental, Social and Governance Report
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces 2023 Annual Meeting of Shareholder Results
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces U.S. Launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Reports More Than 65 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release First-Quarter 2023 Financial Results on May 3
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb and Heidelberg Engineering Announce the Introduction of SeeLuma™ Fully Digital Surgical Visualization Platform
From Bausch + Lomb
Via Business Wire
Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology
From Bausch + Lomb Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
Via Benzinga
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results
From Bausch + Lomb Corporation
Via Business Wire
Trade Desk, Roblox, Herbalife And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023
From Bausch + Lomb Corporation
Via Business Wire
New Bausch + Lomb Social Media Campaign Highlights What ‘Sights’ Inspire AMD Patients
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)
From Bausch + Lomb Corporation
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.